Leptin by itself doesn't hold promise for weight loss — but a new mouse study suggests it could work in combination with ...

A study in Brazil involving 89 father-mother-baby triads points to an association between paternal overweight and newborn ...

More than half of Americans qualify for GLP-1 receptor agonist drugs, but many can't afford them. Experts share cheaper ...

Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has outperformed its main competitor, Wegovy, in a clinical ...

Adults who take Zepbound lose more weight than those who take competitor weight loss drug Wegovy, according to new clinical ...

Millions of Americans with obesity would be eligible to have popular weight-loss drugs like Wegovy or Zepbound covered by ...

The strongest influence of cardiovascular risk and obesity on reduced brain volume is seen between 55 and 64 years o ...

Certain types of porridge, crumpets and breakfast cereals are included in a list of products that fall under a new junk food ...

We recently compiled a list of the 10 Best Small-Cap Biotech Stocks with Massive Potential According to Hedge Funds. In this ...

Obesity and visceral fat are associated with measures of amyloid burden in the brain among cognitively normal midlif ...

People who took Zepbound, Eli Lilly’s weight loss drug, shed more pounds than those on Novo Nordisk’s Wegovy in a clinical ...

W ith more people taking the weight-loss drugs Wegovy and Zepbound, one question inevitably arises: which one is more ...